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See related research by Sakr et al., http://ccforum.com/content/18/2/R68Sakr and colleagues report seemingly disappointing data
on the effects of selenium in severe sepsis [1]. Mortality
rates remained unaffected despite intensive selenium
supplementation. The authors conclude that extra selen-
ium above a basal supply of 100 μg/day provides no
additional health benefit.
However, there are good reasons for selenium supple-
mentation in sepsis; the selenium status declines with the
disease especially in nonsurvivors [2], reducing selenopro-
tein P levels [3], while supplemental selenium efficiently re-
stores selenoprotein expression in experimental models [4].
Yet some major questions prevail. Is it sufficient to
balance selenium decline (substitution)? Are larger dosages
required for overcoming compromised selenoprotein bio-
synthesis (supplementation)? Are bolus dosages of selenite
key to health benefits (pro-oxidative)? For me, the third
option has been specifically disproven by the data [1].Correspondence: lutz.schomburg@charite.de
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2014So why does this study seemingly contradict the
positive findings of Angstwurm and colleagues [5]? An
answer may be deduced from the comparison of the
selenium and selenoprotein concentrations before and
during supplementation. However, these data are un-
fortunately not provided. The perception of selenium in
medicine currently assumes a J-shaped curve relation-
ship between intake and effects; that is, conferring health
benefits upon supplementation only for the deficient
individuals. We thus need to monitor the selenium
status of critically ill patients to better understand its
importance and to identify those patients in need of
supplemental selenium. While the optimal dosage
remains to be determined, a pro-oxidative bolus has
been disqualified without calling selenium supple-
mentation in dosages beyond pure substitution into
question.We read with interest the letter by Dr Schomburg
concerning our article published recently in Critical Care
[1]. He interpreted the results of this study as disproving a
possible beneficial effect of bolus selenite supplementation
in patients with severe sepsis. However, the limitations of
our study must be taken into consideration before reaching
this conclusion. The retrospective design may have intro-
duced bias by indication, with selenium given only to the
more severely ill patients. In addition, some factors that
may impact on outcomes were not included in the multi-
variate analysis; for example, the nature and severity of
surgical complications in individual patients. Nevertheless,
with these limitations in mind, our data do suggest that
surgical ICU patients with severe sepsis may not benefitfrom adjuvant selenium supplementation with the dosage
used in our study.
Dr Schomburg also suggests that selenium supplemen-
tation may be beneficial in patients with selenium defi-
ciency [2], and refers to the earlier study of Angstwurm
and colleagues [5] to support this assumption. Although
this study reported selenium levels in patients included in
the analysis, it did not provide clear evidence to confirm
the assumption because selenium levels were similar at
baseline between the study groups. The discrepancy
between our results [1] and those of Angstwurm and
colleagues [5] may be attributed to the differences in case
mix. A recently completed multicenter study, the Placebo
Controlled Trial of Sodium Selenite and Procalcitonin
Guided Antimicrobial Therapy in Severe Sepsis (SISPCT,
ClinicalTrials.gov NCT00832039), will hopefully provide
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